A 12-month therapy with Mepolizumab dramatically improved Chronic rhinosinusitis with nasal polyps (CRSwNP) outcomes in adults with severe asthma, according to a recent study. In this multicentric real-life retrospective study, Stefania Gallo et al. aimed to assess the efficacy of Mepolizumab on the sinonasal outcomes of severe asthma and concomitant CRSwNP.

In total, 43 individuals with severe asthma who were treated with Mepolizumab and had comorbid CRSwNP were included. Assessment of blood eosinophil count, SinoNasal Outcome Test (SNOT)-22, and Nasal Polyp (NP) scores at baseline and 12 months were the major outcomes. The secondary outcomes were to estimate Mepolizumab’s effects on the aforementioned parameters, recognize variables affecting the degree of response to therapy, and characterize responder and nonresponder patients.

After 12 months of therapy, a clinically meaningful decrease in mean SNOT-22 score, median NP score, and mean blood eosinophil count was seen, as depicted in Table 1:

Overall, 20 volunteers (47%) experienced improvements in their endoscopic and clinical results. Patients who responded to Mepolizumab showed a baseline SNOT-22 that was considerably greater than that of non-responders. Hence, for the management of severe asthmatic patients with comorbid CRSwNP, Mepolizumab use was found to be valuable. These early assessments would need to be supplemented by more research.